{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:43:34Z","timestamp":1793119414571,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>For the first time in nearly half a century, fatty liver disease has undergone a change in name and definition, from the exclusive term, non-alcoholic fatty liver disease (NAFLD), to the inclusion-based, metabolic-associated fatty liver disease (MAFLD). This has led investigators across the globe to evaluate the impact the nomenclature change has had on the epidemiology and natural history of the disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This systematic review provides a comprehensive overview on how the shift in name and diagnostic criteria has influenced point prevalence in different geographic regions, as well as morbidity and mortality risk, whilst highlighting gaps in the literature that need to be addressed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>MAFLD prevalence is higher than NAFLD prevalence, carries a higher risk of overall mortality, with greater granularity in risk-stratification amongst MAFLD subtypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Graphical abstract<\/jats:title><\/jats:sec>","DOI":"10.1007\/s12072-023-10568-z","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T11:02:31Z","timestamp":1691578951000},"page":"1082-1097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6427-6140","authenticated-orcid":false,"given":"Karl","family":"Vaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Clayton-Chubb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart K.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"issue":"7","key":"10568_CR1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","volume":"55","author":"J Ludwig","year":"1980","unstructured":"Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55(7):434\u2013438","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10568_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73\u201384","journal-title":"Hepatology"},{"issue":"6","key":"10568_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100192","volume":"2","author":"P Burra","year":"2020","unstructured":"Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: disease burden, current management and future challenges. JHEP Rep 2020;2(6): 100192","journal-title":"JHEP Rep"},{"issue":"2","key":"10568_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20294","volume":"3","author":"RJ Wong","year":"2020","unstructured":"Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014\u20132019. JAMA Netw Open 2020;3(2): e1920294","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10568_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"7","key":"10568_CR6","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"Eslam M, Sanyal AJ, George J, International Consensus P","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158(7):1999-2014.e1","journal-title":"Gastroenterology"},{"issue":"6","key":"10568_CR7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O","year":"2016","unstructured":"European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388\u2013402","journal-title":"J Hepatol"},{"issue":"1","key":"10568_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328\u2013357","journal-title":"Hepatology"},{"issue":"3","key":"10568_CR9","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.31420","volume":"73","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 2021;73(3):1194\u20131198","journal-title":"Hepatology"},{"issue":"4","key":"10568_CR10","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jhep.2020.10.015","volume":"74","author":"SP Singh","year":"2021","unstructured":"Singh SP, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, et al. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol 2021;74(4):972\u2013974","journal-title":"J Hepatol"},{"issue":"6","key":"10568_CR11","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.jhep.2020.08.028","volume":"73","author":"V Ratziu","year":"2020","unstructured":"Ratziu V, Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, et al. The times they are a-changin\u2019 (for NAFLD as well). J Hepatol 2020;73(6):1307\u20131309","journal-title":"J Hepatol"},{"issue":"6","key":"10568_CR12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14(6):889\u2013919","journal-title":"Hepatol Int"},{"key":"10568_CR13","unstructured":"AASLD. Reaching Consensus on NAFLD Nomenclature 2022 [Available from: https:\/\/www.aasld.org\/news\/reaching-consensus-nafld-nomenclature."},{"key":"10568_CR14","unstructured":"EASL. NAFLD Nomenclature Consensus Meeting High-Level Output 2022 [Available from: https:\/\/easl.eu\/news\/nafld-nomenclature-consensus-meeting-high-level-output\/."},{"issue":"9","key":"10568_CR15","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14548","volume":"40","author":"S Lin","year":"2020","unstructured":"Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40(9):2082\u20132089","journal-title":"Liver Int"},{"issue":"1","key":"10568_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.102063","volume":"47","author":"P Zhang","year":"2023","unstructured":"Zhang P, Dong X, Zhang W, Wang S, Chen C, Tang J, et al. Metabolic-associated fatty liver disease and the risk of cardiovascular disease. Clin Res Hepatol Gastroenterol 2023;47(1): 102063","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10568_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.693507","volume":"8","author":"Q Huang","year":"2021","unstructured":"Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-Results from NHANES III. Front Med (Lausanne) 2021;8: 693507","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10568_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/liv.13992","volume":"39","author":"J Paik","year":"2019","unstructured":"Paik J, Golabi P, Younoszai Z, Mishra A, Trimble G, Younossi ZM. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int 2019;39(2):342\u2013352","journal-title":"Liver Int"},{"issue":"6","key":"10568_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","volume":"10","author":"M Stepanova","year":"2012","unstructured":"Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012;10(6):646\u2013650","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10568_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6891","volume":"343","author":"M Lazo","year":"2011","unstructured":"Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011;343: d6891","journal-title":"BMJ"},{"issue":"1","key":"10568_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/aje\/kws448","volume":"178","author":"M Lazo","year":"2013","unstructured":"Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988\u20131994. Am J Epidemiol 2013;178(1):38\u201345","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10568_CR22","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","volume":"19","author":"VH Nguyen","year":"2021","unstructured":"Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons With NAFLD and\/or MAFLD. Clin Gastroenterol Hepatol 2021;19(10):2172\u201381 e6","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10568_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2023.114720","volume":"254","author":"R Aimuzi","year":"2023","unstructured":"Aimuzi R, Xie Z, Qu Y, Jiang Y, Luo K. Associations of urinary organophosphate esters metabolites and diet quality with nonalcoholic\/metabolic dysfunction-associated fatty liver diseases in adults. Ecotoxicol Environ Saf 2023;254: 114720","journal-title":"Ecotoxicol Environ Saf"},{"issue":"6","key":"10568_CR24","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/liv.14828","volume":"41","author":"S Ciardullo","year":"2021","unstructured":"Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int 2021;41(6):1290\u20131293","journal-title":"Liver Int"},{"key":"10568_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.795391","volume":"8","author":"ZQ Xie","year":"2021","unstructured":"Xie ZQ, Li HX, Tan WL, Yang L, Ma XW, Li WX, et al. Association of serum vitamin C With NAFLD and MAFLD among adults in the United States. Front Nutr 2021;8: 795391","journal-title":"Front Nutr"},{"issue":"3","key":"10568_CR26","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1016\/j.cgh.2021.01.030","volume":"20","author":"RJ Wong","year":"2022","unstructured":"Wong RJ, Cheung R. Trends in the prevalence of metabolic dysfunction-associated fatty liver disease in the United States, 2011\u20132018. Clin Gastroenterol Hepatol 2022;20(3):e610\u2013e613","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"10568_CR27","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1097\/CM9.0000000000001513","volume":"134","author":"HJ Zhang","year":"2021","unstructured":"Zhang HJ, Wang YY, Chen C, Lu YL, Wang NJ. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999\u20132016. Chin Med J (Engl) 2021;134(13):1593\u20131601","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"10568_CR28","first-page":"777","volume":"11","author":"X Xu","year":"2023","unstructured":"Xu X, Zhou X, Tian T, Ding Y, Yu C, Zhao W, et al. Comparison of clinical characteristics and outcomes of MAFLD and NAFLD in Chinese Health examination populations. J Clin Transl Hepatol 2023;11(4):777\u2013786","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"10568_CR29","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1210\/clinem\/dgab644","volume":"107","author":"X Wang","year":"2022","unstructured":"Wang X, Wu S, Yuan X, Chen S, Fu Q, Sun Y, et al. Metabolic dysfunction-associated fatty liver disease and mortality among chinese adults: a prospective cohort study. J Clin Endocrinol Metab 2022;107(2):e745\u2013e755","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10568_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab 2022;107(1):88\u201397","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10568_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14218\/JCTH.2021.00089","volume":"10","author":"C Yu","year":"2022","unstructured":"Yu C, Wang M, Zheng S, Xia M, Yang H, Zhang D, et al. Comparing the diagnostic criteria of MAFLD and NAFLD in the Chinese population: a population-based prospective cohort study. J Clin Transl Hepatol 2022;10(1):6\u201316","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10568_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/s12876-022-02576-4","volume":"22","author":"Q Liu","year":"2022","unstructured":"Liu Q, Zhao G, Li Q, Wu W, Zhang Y, Bian H. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study. BMC Gastroenterol 2022;22(1):471","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"10568_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.14218\/JCTH.2021.00306","volume":"10","author":"L Miao","year":"2022","unstructured":"Miao L, Yang L, Guo LS, Shi QQ, Zhou TF, Chen Y, et al. Metabolic dysfunction-associated fatty liver disease is associated with greater impairment of lung function than nonalcoholic fatty liver disease. J Clin Transl Hepatol 2022;10(2):230\u2013237","journal-title":"J Clin Transl Hepatol"},{"key":"10568_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.968766","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yu Y, Zhang H, Chen C, Wan H, Chen Y, et al. Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China. Front Endocrinol (Lausanne) 2022;13: 968766","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10568_CR35","doi-asserted-by":"crossref","unstructured":"Yuan X, Wang X, Wu S, Chen S, Wang Y, Wang J, Lu Y, Sun Y, Fu Q, Wang L. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China. HepatoBiliary Surg Nutr 2022. https:\/\/hbsn.amegroups.org\/article\/view\/96588\/pdf","DOI":"10.21037\/hbsn-21-546"},{"issue":"2","key":"10568_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.hbpd.2022.01.006","volume":"21","author":"J Zeng","year":"2022","unstructured":"Zeng J, Qin L, Jin Q, Yang RX, Ning G, Su Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: a community-based study. Hepatobiliary Pancreat Dis Int 2022;21(2):154\u2013161","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"10","key":"10568_CR37","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.cgh.2020.10.046","volume":"19","author":"VW Wong","year":"2021","unstructured":"Wong VW, Wong GL, Woo J, Abrigo JM, Chan CK, Shu SS, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol 2021;19(10):2161\u201371.e5","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10568_CR38","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12072-022-10449-x","volume":"17","author":"YM Cheng","year":"2023","unstructured":"Cheng YM, Wang CC, Kao JH. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications. Hepatol Int 2023;17(2):350\u2013356","journal-title":"Hepatol Int"},{"issue":"10","key":"10568_CR39","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol 2021;19(10):2138\u201347.e10","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10568_CR40","doi-asserted-by":"crossref","unstructured":"Chun HS, Lee M, Lee JS, Lee HW, Kim BK, Park JY, et al. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease. Liver Int 2022. https:\/\/pubmed.ncbi.nlm.nih.gov\/36585250\/","DOI":"10.1111\/liv.15508"},{"key":"10568_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.844954","volume":"9","author":"JM Choi","year":"2022","unstructured":"Choi JM, Park HE, Han YM, Lee J, Lee H, Chung SJ, et al. Non-alcoholic\/metabolic-associated fatty liver disease and helicobacter pylori additively increase the risk of arterial stiffness. Front Med (Lausanne) 2022;9: 844954","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10568_CR42","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1007\/s10620-022-07508-6","volume":"67","author":"H Kim","year":"2022","unstructured":"Kim H, Lee CJ, Ahn SH, Lee KS, Lee BK, Baik SJ, et al. MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig Dis Sci 2022;67(10):4919\u20134928","journal-title":"Dig Dis Sci"},{"key":"10568_CR43","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0327","author":"KS Kim","year":"2023","unstructured":"Kim KS, Hong S, Ahn HY, Park CY. Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study. Diabetes Metab J 2023. https:\/\/doi.org\/10.4093\/dmj.2021.0327","journal-title":"Diabetes Metab J"},{"issue":"10","key":"10568_CR44","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3390\/biomedicines9101401","volume":"9","author":"JY Seo","year":"2021","unstructured":"Seo JY, Bae JH, Kwak MS, Yang JI, Chung SJ, Yim JY, et al. The risk of colorectal adenoma in nonalcoholic or metabolic-associated fatty liver disease. Biomedicines 2021;9(10):1401","journal-title":"Biomedicines"},{"issue":"5","key":"10568_CR45","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.numecd.2023.01.013","volume":"33","author":"TK Yoo","year":"2023","unstructured":"Yoo TK, Lee MY, Kim SH, Zheng MH, Targher G, Byrne CD, et al. Comparison of cardiovascular mortality between MAFLD and NAFLD: a cohort study. Nutr Metab Cardiovasc Dis 2023;33(5):947\u2013955","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10568_CR46","doi-asserted-by":"publisher","first-page":"13844","DOI":"10.1038\/s41598-021-93435-x","volume":"11","author":"H Fujii","year":"2021","unstructured":"Fujii H, Fukumoto S, Enomoto M, Uchida-Kobayashi S, Kimura T, Tamori A, et al. The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. Sci Rep 2021;11(1):13844","journal-title":"Sci Rep"},{"issue":"5","key":"10568_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269265","volume":"17","author":"R Bessho","year":"2022","unstructured":"Bessho R, Kashiwagi K, Ikura A, Yamataka K, Inaishi J, Takaishi H, et al. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. PLoS\u00a0One 2022;17(5): e0269265","journal-title":"PLoS\u00a0One"},{"issue":"11","key":"10568_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277930","volume":"17","author":"T Tateda","year":"2022","unstructured":"Tateda T, Iino C, Sasada T, Sato S, Igarashi G, Kawaguchi S, et al. Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: a large cross-sectional study. PLoS\u00a0One 2022;17(11): e0277930","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"10568_CR49","doi-asserted-by":"publisher","first-page":"16048","DOI":"10.1038\/s41598-022-20124-8","volume":"12","author":"M Sogabe","year":"2022","unstructured":"Sogabe M, Okahisa T, Kurihara T, Kagawa M, Ueda H, Kawaguchi T, et al. Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females. Sci Rep 2022;12(1):16048","journal-title":"Sci Rep"},{"issue":"3","key":"10568_CR50","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/ndt\/gfac188","volume":"38","author":"M Tanaka","year":"2023","unstructured":"Tanaka M, Mori K, Takahashi S, Higashiura Y, Ohnishi H, Hanawa N, et al. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease. Nephrol Dial Transplant 2023;38(3):700\u2013711","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10568_CR51","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41440-023-01179-0","volume":"46","author":"K Mori","year":"2023","unstructured":"Mori K, Tanaka M, Hosaka I, Mikami T, Endo K, Hanawa N, et al. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses. Hypertens Res 2023;46(5):1110\u20131121","journal-title":"Hypertens Res"},{"issue":"2","key":"10568_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245762","volume":"16","author":"MA Niriella","year":"2021","unstructured":"Niriella MA, Ediriweera DS, Kasturiratne A, De Silva ST, Dassanayaka AS, De Silva AP, et al. Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study. PLoS\u00a0One 2021;16(2): e0245762","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"10568_CR53","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jgh.15723","volume":"37","author":"W Kemp","year":"2022","unstructured":"Kemp W, Clayton-Chubb D, Majeed A, Glenister KM, Magliano DJ, Lubel J, et al. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. J Gastroenterol Hepatol 2022;37(2):395\u2013403","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10568_CR54","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/hep.32131","volume":"75","author":"LA van Kleef","year":"2022","unstructured":"van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: the Rotterdam Study. Hepatology 2022;75(2):419\u2013429","journal-title":"Hepatology"},{"issue":"6","key":"10568_CR55","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol 2021;75(6):1284\u20131291","journal-title":"J Hepatol"},{"issue":"5","key":"10568_CR56","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/hep.32499","volume":"76","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology 2022;76(5):1423\u20131437","journal-title":"Hepatology"},{"issue":"4","key":"10568_CR57","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s12072-022-10362-3","volume":"16","author":"YC Zhang","year":"2022","unstructured":"Zhang YC, Lyu ZY, Ma B, Li LM, Wang W, Sheng C, et al. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. Hepatol Int 2022;16(4):835\u2013845","journal-title":"Hepatol Int"},{"issue":"3","key":"10568_CR58","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5009\/gnl210167","volume":"16","author":"JH Moon","year":"2022","unstructured":"Moon JH, Kim W, Koo BK, Cho NH, Innovative Target Exploration of Nc. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease. Gut Liver 2022;16(3):433\u201342","journal-title":"Gut Liver"},{"issue":"11","key":"10568_CR59","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","volume":"56","author":"M Yoneda","year":"2021","unstructured":"Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol 2021;56(11):1022\u20131032","journal-title":"J Gastroenterol"},{"issue":"2","key":"10568_CR60","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","volume":"41","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 2018;41(2):372\u2013382","journal-title":"Diabetes Care"},{"issue":"1","key":"10568_CR61","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut 2022;71(1):156\u2013162","journal-title":"Gut"},{"issue":"4","key":"10568_CR62","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut 2022;71(4):778\u2013788","journal-title":"Gut"},{"issue":"5","key":"10568_CR63","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","volume":"70","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 2021;70(5):962\u2013969","journal-title":"Gut"},{"key":"10568_CR64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","volume":"79","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism 2018;79:64\u201376","journal-title":"Metabolism"},{"issue":"7","key":"10568_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001680","volume":"11","author":"G Musso","year":"2014","unstructured":"Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11(7): e1001680","journal-title":"PLoS Med"},{"issue":"2","key":"10568_CR66","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","volume":"20","author":"LA Orci","year":"2022","unstructured":"Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin Gastroenterol Hepatol 2022;20(2):283\u201392 e10","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10568_CR67","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016;65(3):589\u2013600","journal-title":"J Hepatol"},{"issue":"1","key":"10568_CR68","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000435","volume":"13","author":"H Lee","year":"2022","unstructured":"Lee H, Lee HW, Kim SU, Chang KH. Metabolic dysfunction-associated fatty liver disease increases colon cancer risk: a nationwide cohort study. Clin Transl Gastroenterol 2022;13(1): e00435","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"10568_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100231","volume":"3","author":"S Myers","year":"2021","unstructured":"Myers S, Neyroud-Caspar I, Spahr L, Gkouvatsos K, Fournier E, Giostra E, et al. NAFLD and MAFLD as emerging causes of HCC: a populational study. JHEP Rep 2021;3(2): 100231","journal-title":"JHEP Rep"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10568-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10568-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10568-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T22:43:23Z","timestamp":1729896203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10568-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10568"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10568-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Karl Vaz, Daniel Clayton-Chubb, Ammar Majeed, John Lubel, David Simmons, William Kem, Stuart K. Roberts declares that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}